Acutaas Chemicals Limited Stocks

1093.2Last Updated 24.06.2025

Issuer Rating

4/7
Performance

Modest

Risk

Limited

Recommendation

Hold

Market Cap

₹ 1.03B

Buy
Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
1093.2
Key Takeaways

Risk factor

Moderate default risk

Data is available to registered users only
Data is available to registered users only

Profitability factor

Strong growth

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Ami Organics Limited engages in the research and development, manufacture, and sale of pharmaceutical intermediates in India. The company offers approximately 450 pharma intermediates for use in regulated and generic active pharmaceutical ingredients for anti-retroviral, anti-inflammatory, anti-psychotic, anti-cancer, anti-parkinson, antidepressant, and anticoagulant applications, as well as in new chemical entities. It also provides preservatives, such as parabens and parabens formulations for use in cosmetics, animal food, and personal care industries; and specialty chemicals for use in cosmetics, dyes, polymers, and agrochemicals. In addition, the company exports its products. Ami Organics Limited was founded in 2004 and is based in Surat, India.

Company Valuation

Greatly overvalued
1/7

From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks. Specifically, the stock is 'expensive' on P/E, overvalued

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Neutral
4/7

The average target price of AMIORG.NS is 1359 and suggests 16% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to i

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis
X-channel

Buy

Sell

0 more stocks